Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Krystexxa Cleared For Refractory Gout, Could Reach Patients By Year's End

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite black box warning for anaphylaxis and infusion reactions, label and risk plan are seen as "benign" by analysts.
Advertisement

Related Content

Private Equity-Backed Crealta Makes Its First Move With Savient Deal
AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate
Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
Savient's New CEO Johnson Tasked With Turning Krystexxa Into A Commercial Success
Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch
Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
Gout Pipeline Looks Past Uloric To Resistant Patients, Acute Flares

Topics

Advertisement
UsernamePublicRestriction

Register

PS071176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel